EANS-Adhoc: Marinomed Biotech AG resumes offer period of the IPO

--------------------------------------------------------------------------------
Disclosed inside information pursuant to article 17 Market Abuse Regulation
(MAR) transmitted by euro adhoc with the aim of a Europe-wide distribution.
The issuer is responsible for the content of this announcement.
--------------------------------------------------------------------------------

Stock Offerings (IPO)
23.01.2019

Vienna - 23 January 2019. Marinomed Biotech AG has decided to resume its initial
public offering and listing on the Vienna Stock Exchange (the "Offering"). The
Offer Period that was suspended on 29 November 2018 will be resumed on and
including Thursday 24 January 2019 and is expected to end on Tuesday 29 January
2019. The Offering comprises a public offering to retail and institutional
investors in Austria, a private placement outside Austria to selected
institutional investors, including a private placement within the United States
of America to qualified institutional buyers in reliance on Rule 144A under the
US Securities Act of 1933, as amended, and a private placement outside of the
United States of America to certain other eligible institutional investors in
reliance on Regulation S under the US Securities Act of 1933, as amended.

The Price Range for the offered shares of EUR 75 to 90 per share remains
unchanged. The final Offer Price is expected to be determined and announced on
29 January 2019. The expected settlement date and first trading day is 1
February 2019. From this date the Marinomed shares are intended to be traded
under the symbol "MARI" on the official market (prime market segment) of the
Vienna Stock Exchange.

The Offering size has been adapted and comprises up to 260,000 new bearer shares
(base size), which may be increased by up to 40,000 new bearer shares (the
upsize option). In addition, the Offering may be increased by up to a further
15% (up to 45,000 new bearer shares) on top of the base size and the upsize
option, if any, through exercise of an over-allotment option (greenshoe option).
The gross proceeds of the Offering based on the Price Range is thus supposed to
be between EUR 22.4m (at the lower end of the price range, without exercise of
the upsize option and including the exercise of the greenshoe option) and EUR
31.1m (at the upper end of the price range, including exercise of the upsize
option and greenshoe option).

The proceeds from the Offering shall be used primarily to fund the Pivotal Phase
III study of Budesolv, Phase II and Phase III studies of Tacrosolv as well as
the extension of the Carragelose OTC platform.

The transaction meets the requirements of a qualified public offer in accordance
with the terms and conditions of the convertible bonds issued in 2017 that are
traded on the Third Market of the Vienna Stock Exchange. Following successful
completion of the Offering, convertible bondholders are expected to be entitled
from 1 February 2019 to convert their bonds into new shares of Marinomed Biotech
AG in accordance with the terms and conditions of the convertible bond (start of
conversion period, which, according to the terms and conditions of the
convertible bonds, lasts two weeks, hence until and including 14 February 2019).
The Conversion Price I (as defined in the terms and conditions of the
convertible bonds) to be adjusted on the basis of the final Offer Price is
expected to be determined and announced on 29 January 2019.

Marinomed Biotech AG reserves the right to premature termination, interruption
or suspension of the Offering, extension or shortening of the Offer Period.

About Marinomed Biotech AG
Marinomed Biotech AG is a Vienna based biopharmaceutical company focusing on the
development of innovative products derived from patent protected technology
platforms to treat respiratory and ophthalmic conditions. The Carragelose®
platform comprises innovative patent protected products targeting viral
infections of the respiratory tract. Carragelose® is used in nasal sprays,
throat sprays and lozenges, which are sold in more than 30 countries around the
world in collaboration with international partners. The Marinosolv® technology
platform increases the efficacy of hardly soluble compounds for the treatment of
sensitive tissues such as the eyes and nose. Further information is available at
www.marinomed.com.

Disclaimer

This announcement does not constitute an offer to purchase securities or
solicitation of an offer to purchase securities in the United States of America,
Germany, Austria or other jurisdictions. The shares (the "Shares") of Marinomed
Biotech AG (the "Company") may only be sold or offered for sale after prior
registration in the United States of America upon or without prior registration
by virtue of an exemption from the registration requirement under the provisions
of the US Securities Act of 1933, as amended. The Company does not intend to
fully or partially register any offer of Shares in the United States or to make
any public offering of Shares in the United States.

A public offering of securities of the Company in Austria is made solely by, and
on the basis of, a prospectus (including the supplements thereto) for securities
prepared and published in accordance with the provisions of the Capital Markets
Act (Kapitalmarktgesetz), which was approved and published on 16 November 2018.
An investment decision regarding publicly offered securities of the Company
should only be made on the basis of such a prospectus. Any purchase orders
relating to securities of the Company received prior to the resumption of the
public offering will be rejected. The prospectus as well as the supplements
thereto are available free of charge at Marinomed Biotech AG, Veterinärplatz 1,
A-1210 Vienna, or on the website of Marinomed Biotech AG (https://
www.marinomed.com/offering).

Further inquiry note:
Eva Prieschl-Grassauer, PhD
Chief Scientific Officer, Marinomed
Veterinärplatz 1, 1210 Vienna, Austria
Tel.: +43 (0)1 250 77 4460
E-mail: eva.prieschl@marinomed.com
http://www.marinomed.com

Roland Mayrl
Managing Partner, Metrum Communications
Prinz-Eugen-Straße 80/16, 1040 Vienna, Austria
Tel.: +43 (0) 1 504 69 87 331
E-mail: r.mayrl@metrum.at
http://www.metrum.at

end of announcement euro adhoc
--------------------------------------------------------------------------------

issuer: Marinomed Biotech AG
Veterinärplatz 1
A-1210 Wien
phone: 0043250774460
FAX: 0043250774493
mail: office@marinomed.com
WWW: www.marinomed.com
ISIN: AT0000A1WD52, ATMARINOMED6
indexes:
stockmarkets: Wien
language: English

Original-Content von: Marinomed Biotech AG, übermittelt durch news aktuell